SYDNEY, Australia – CSL Limited (ASX:CSL; USOTC:CSLLY) is gradually improving its Research & Development (R&D) pipeline and capabilities to deliver a greater range of products that will meet the standards of patients’ needs, according to Head of Research & Development Dr. William Mezzanotte.
Dr. Mezzanotte pointed out that the company is building on its role in plasma therapy by identifying promising new medic....
Tags : R&D Capabilities, CSL Continues, Advance R&D, unique treatment , ,
comments (0)